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Antiviral therapya b s t r a c t
The 27th International Conference on Antiviral Research (ICAR) was held in Raleigh, North Carolina, USA
fromMay 12 to 16, 2014. This article summarizes the principal invited lectures. John Drach (Elion Award)
described the early days of antiviral drugs and their novel modes of action. Piet Herdewijn (Holy´ Award)
used evolutionary pressure to select DNA polymerases that accept nucleoside analogs. Replacing thymine
by 5-chlorouracil led to the generation of a new form of Escherichia coli. Adrian Ray (Prusoff Award) dem-
onstrated how prodrugs can markedly improve both the efﬁcacy and safety of potential drugs. The key-
note addresses, by David Margolis and Myron Cohen, tackled two emerging areas of HIV research, to ﬁnd
an HIV ‘‘cure’’ and to prevent HIV transmission, respectively. These topics were discussed further in other
presentations – a cure seems to be a distant prospect but there are exciting developments for reducing
HIV transmission. TDF-containing vaginal rings and GSK-744, as a long-lasting injection, offer great hope.
There were three mini-symposia. Although therapy with TDF/FTC gives excellent control of HBV replica-
tion, there are only a few patients who achieve a functional cure. Myrcludex, an entry inhibitor, is active
against both HBV and HDV. The recent progress with HBV replication in cell cultures has transformed the
search for new antiviral compounds. The HBV capsid protein has been recognized as key player in HBV
DNA synthesis. Unexpectedly, compounds which enhance capsid formation, markedly reduce HBV
DNA synthesis. The development of BCX4430, which is active against Marburg and Ebola viruses, is of
great current interest.
 2014 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-SA license
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This article provides an overview of the invited lectures at the
27th International Conference on Antiviral Research, sponsored
by the International Society for Antiviral Research (ISAR), which
was held in Raleigh, North Carolina, USA from May 12 to 16,
2014. It begins with reports of lectures by the recipients of ISAR’s
three major awards, held in memory of Gertrude Elion, Antonín
Holy´ and William Prusoff. These are followed by brief summaries
of the keynote addresses and the three mini-symposia on ‘‘Hepati-
tis B virus’’, ‘‘Research Triangle Park’’ and ‘‘Challenges in HIV infec-
tion, treatment and prevention’’. Because this review article simply
provides short accounts of oral presentations, it is not generally
accompanied by references to the scientiﬁc literature. Any descrip-
tions of favorable treatment outcomes should not be taken as rec-
ommendations for clinical use.2. Gertrude Elion memorial award lecture: collaborative
antiviral studies for the discovery of drugs to treat
cytomegalovirus infections
John C. Drach, Ph.D., University of Michigan, Ann Arbor, Michi-
gan, USA (Fig. 1).
Gertrude B. (Trudy) Elion was born in New York City and was
pleased to work for the Burroughs Wellcome Co. when based in
New York but was concerned when it transferred to Research
Triangle Park, North Carolina, not many miles from this year’s
meeting site. However, within just a few months she declared that
she was ‘‘at home’’ in North Carolina. She was awarded the Nobel
Prize in Physiology or Medicine in 1988 for her pioneering work inFig. 1. Phil Furman presenting the Elion Award to John Drach.purine biosynthesis which paved the way for the discovery of
drugs to treat organ rejection, cancer and viral diseases.
The focusof John’spresentationwason the researchconducted in
his own and his collaborators’ laboratories that ultimately led to the
invention of three compounds which were discovered to have anti-
viral activity against human cytomegalovirus (HCMV) and which
later entered clinical trials: BDCRBpyranoside (GW275175X) (Phase
I), maribavir (Phases I, II and III) and cyclopropavir (Phase I). His
major collaborators included Karen Biron, Charles Shipman, Leroy
Townsend, and Jiri Zemlicka. To date, there are only ﬁve FDA-
approved drugs for treatment of HCMV infections: cidofovir, fomi-
virsen, foscarnet, ganciclovir and valganciclovir.
Being inspired by the presence of a naturally-occurring 5,6-
dimethylbenzimidazole nucleotide in Vitamin B12, research on
benzimidazole nucleosides was initiated by medicinal chemists
in the 1950s and ’60s. This led to the synthesis of a trichloro analog
in Townsend’s laboratory at the University of Utah and later the
discovery of its activity against HCMV in John’s laboratory. Much
work, in both their laboratories at the University of Michigan,
established that it and its 2-bromo analog (BDCRB) have excellent
activity against HCMV with very low cytotoxicity. Surprisingly, it
was found to be inactive against other herpes viruses and it did
not need conversion to a triphosphate to be active against HCMV.
Collaborative studies with Karen Biron at Burroughs Wellcome
established that, unlike many other anti-virals that inhibit viral
DNA synthesis such as ganciclovir (GCV), these compounds actedFig. 2. Structures of BDCRB, BDCRB pyranoside and maribavir.
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the viral resistance studies which revealed the viral targets,
pUL89 and pUL56. These two proteins, with pUL104, form a com-
plex known as the terminase which cuts newly synthesised HCMV
DNA into unit lengths for packaging into virions. Although BDCRB
had many desirable properties in vitro, it had poor pharmacokinet-
ics in mice and monkeys due to hydrolysis of its glycosidic bond;
therefore it was not developed for human use. Much additional
work in Drach’s and Townsend’s laboratories at Michigan and by
Biron’s group at Burroughs Wellcome ultimately led to two poten-
tial drug candidates, BDCRB pyranoside and maribavir (Fig. 2). Both
compounds have excellent activity against HCMV, low toxicity, and
excellent pharmacokinetics. Clearly, their modes of action differed
markedly from that of GCV. Quite unexpectedly, they have differ-
ent mechanisms of action.
BDCRB pyranoside has a mechanism of action very similar to its
parent compound BDCRB, inhibition of DNA processing. In con-
trast, maribavir inhibits DNA synthesis, albeit indirectly. It is a 2-
isopropylamine derivative of BDCRB except that it has the unnatu-
ral L-sugar conﬁguration. Its mechanism of action involves inhibi-
tion of the viral kinase (pUL97), which phosphorylates another
viral protein, pUL44. Phosphorylated pUL44 is necessary for viral
DNA synthesis. Thus inhibition of pUL97 by maribavir inhibits viral
DNA synthesis. Interestingly, pUL97 is also the kinase that acti-
vates (phosphorylates) GCV. Resistance studies conﬁrmed that a
single mutation in UL97, resulting in a mutation in the kinase
(Leu397Arg), was necessary and sufﬁcient for resistance to mariba-
vir. In a further study of resistance, virus already resistant to
BDCRB was passaged in increasing concentrations of maribavir
and resistant virus was isolated. This strain grew at the same rate
as the wild-type virus and was resistant to both BDCRB and mari-
bavir. As expected, resistance to BDCRB was due to known muta-
tions in UL56 and UL89. However, no mutations were found in
UL97. Further investigation showed that a single base change in
UL27 (T1004C) was necessary and sufﬁcient for resistance to mar-
ibavir. The role of the encoded protein was then unknown but the
amino acid mutation (Leu335Pro) is in the middle of the protein.
Similarly, Biron’s group detected resistance due to mutations in
the UL27 gene. Further research studies on maribavir have been
summarized in previous ICAR scientiﬁc reports.
Cyclopropavir (CPV, Fig. 3) was synthesized in the laboratory of
Jiri Zemlicka, Karmanos Cancer Institute, Detroit, Michigan. It is a
guanosine nucleoside analog which is very active against HCMV.
Unlike the benzimidazole nucleosides, it also inhibits Epstein-Barr
virus (EBV) and human herpesvirus 8 (HHV-8). Like GCV, it is phos-
phorylated by the kinase encoded by UL97. It is more potent
in vitro and in vivo than ganciclovir but has a somewhat different
pattern of resistance. In one resistant strain, the key mutation
formed a stop codon resulting in a truncated pUL97 kinase protein.
The phosphorylation of CPV by pUL97 is more efﬁcient than that of
GCV, with a considerably lower Km and higher Vmax. Interestingly,
the phosphorylation of CPV to its monophosphate (CPV-MP) by
pUL97 is stereoselective; only the (+) isomer of CPV-MP is formed.
A single enzyme, GMP kinase, phosphorylates CPM-MP to both its







Fig. 3. Structure of cyclopropavir (CPV).additional cellular enzymes to convert their diphosphates to active
triphosphates. Cyclopropavir is currently in Phase I clinical trials
for the treatment of HCMV infections.3. The Antonín Holy´ memorial award lecture: from modiﬁed
nucleoside to a chemically modiﬁed genome
Piet Herdewijn, Rega Institute for Medical Research, KU Leuven,
Belgium (Fig. 4).
The 2013 ICAR began with a symposium, on the legacy of the
late Antonín (Tony) Holy´, at which the establishment of a new ISAR
award in medicinal chemistry was announced. The awardee is to
be a senior scientist of international stature in medicinal chemistry
and who has made innovative contributions impacting antiviral
drug discovery or development. Piet is, therefore, the ﬁrst to
receive this award.
In the late 1970s, the potent activities of BVDU and BVaraU
againstherpes simplexvirus type1 (HSV-1) andvaricella zostervirus
(VZV) were discovered; this work motivated Piet to start antiviral
research with the synthesis of carbocyclic BVDU. Through to the
early 1990s, he synthesized several other nucleoside analogs with
bicyclic bases having good activity against HSV-1 and VZV. During
the 1990s, emphasis switched to investigating the effect of modify-
ing the sugar ring, in particular the synthesis of six-membered rings
containing an oxygen or a double bond. Piet showed examples of
compounds with activity against HSV-1, HSV-2, VZV and HCMV.
Back in 1984, Erik De Clercq showed Piet a paper on AIDS, one of
the authors being Phil Furman. This publication stimulated the
search for anti-HIV compounds. Many compounds were discovered
with potent activities (and good selectivity indices) against HIV.
Piet worked out the ﬁrst structure–activity relationships of anti-
HIV dideoxy nucleosides. Starting in the late 1980s, Tony Holy´ syn-
thesised a series of phosphonates. At the 2013 ICAR, Erik De Clercq
recalled how this work led, ultimately, to tenofovir, which was to
become a major success for treating HIV-infected patients. From
its ﬁrst introduction in 2001, its market share has increased to well
over 40%. In 2002, having a single-pill regimen was agreed as a way
forward to simplify, and thereby enhance, HIV therapy. This led to





















Fig. 5. Structures of deoxyribose and hexitol nucleosides.
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over 130 countries and is distributed widely to the known HIV-
infected population. In line with this research, Piet synthesized
phosphonate nucleosides, with a threose sugar moiety, which
showed anti-HIV activity in the same range as 9-(2-phosphonyl-
methoxyethyl) adenine (PMEA).
Piet’s work had taken a different pathway. It is possible to link
several nucleotides together to form aptamers. For example
(Fig. 5), the above antiviral nucleosides, which have a 6-membered
ring in place of the natural furanose, could be incorporated into hex-
itol nucleic acid (HNA) aptamers. X-ray studies revealed the struc-
tures of HNA–RNA duplexes and HNA–HNA duplexes, the latter
having a similar overall form to that of an RNA–RNA duplex with
the same base sequence. HNA-containing aptamers were shown to
be potent and speciﬁc inhibitors of trans-activating region (TAR)-
mediated transcription. Normally, an HIV encoded protein, trans-
activator of transcription (TAT), binds to cellular factors and to the
viral TAR RNA regulatory element, resulting in a vastly increased
rate of transcription of all HIV genes. HNA-containing aptamers pre-
vents this interaction and so inhibit HIV replication. It took four
years to engineer a polymerase that would utilise HNAs to assemble
a strand complementary to a DNA template. In line with this
research, hexitol-modiﬁed siRNA has shown good activity in an
in vivo anti-HBV model. This success stimulated the concept that it
may be possible to generate new forms of biologically active DNA.
In order to pursue this idea, a culture system with twin growth
chambers was devised. Alternative nutrient media could be fed
into the chambers and the culture from one chamber could be used
to seed the second chamber, the former culture being removed. In
this example, the aim was to replace thymine with 5-chlorouracil
(Fig. 6) using Escherichia coli. Initially, the nutrient contained 10%
5-chlorouracil and 90% thymine. With each cycle, seeding one
chamber from the previous one, the proportion of 5-chlorouracil
was increased. After 180 days, in which there had been about
4000 generations of E. coli, thymine had been replaced totally by
5-chlorouracil. An interesting outcome was that the alternative
base led to a change not only in the genotype but also in the phe-
notype; the ‘‘new’’ E. coli cells were much longer than the original.
This is the ﬁrst example of a DNA polymerase being adapted
through evolutionary pressure to accept a nucleotide analog,
resulting in the generation of a new living organism.Fig. 7. Phil Furman giving the William Prusoff Young Investigator Award to Adrian
Ray.4. The William Prusoff young investigator award lecture: use of
nucleotide prodrugs to enhance selectivity of anti–HIV and –
HCV agents
Adrian S. Ray, Gilead Sciences Inc., Foster City, CA, USA (Fig. 7).
Adrian started his lecture with photos of William (Bill) Prusoff
and reminisced of his days with Bill, Raymond Schinazi and
Yung-Chi (Tommy) Cheng.Adrian presented examples to illustrate two models of how a
prodrug strategy can transform a potential drug into a much
improved clinical candidate. In the ﬁrst, the prodrug alters the dis-
tribution of the pharmacologically active nucleotide analog to tis-
sues where viral infection is taking place (on-target) and away
from tissues resulting in adverse events (off-target). In the second,
the prodrug enables one to select a drug candidate based more
directly on the intrinsic properties of the active nucleotide-triphos-
phate analog via by-passing an inefﬁcient activation (phosphoryla-
tion) of the corresponding nucleoside analog.
Sofosbuvir (Sovaldi), a prodrug of 20-F-20-C-MeUMP, was
approved in the USA on 6th December, 2013 for treatment of
patients with hepatitis C. This is a ﬁne example of a prodrug
enhancing the activity of the parent compound. The nucleoside
analogue, 20-F-20-C-MeU, is poorly active due to restricted phos-
phorylation to the monophosphate. Sofosbuvir, a nucleotide ana-
logue prodrug of 20-F-20-C-MeU, delivers the monophosphate into
the cell and this is then further phosphorylated efﬁciently to give
high levels of the triphosphate which inhibits HCV RNA
polymerase.
Adrian recalled being much impressed by a result reported at
the meeting in 2007 of the American Association for the Study of
Liver Diseases (AASLD). In a Phase II monotherapy trial in patients
with HCV, at day 3, the viral loads were reduced by log103.2 and
log101.1 for VX-950 (1250 mg bid, n=10) and RG-7128 (1500 mg
bid, n=8), respectively. However, from day 4 to 13, the polymerase
inhibitor (RG-7128) had continued to reduce the viral load, reach-
ing a reduction of log102.7. On the other hand, the protease inhib-
itor (VX-950) did not give a sustained reduction, with the viral load
starting to increase from day 6. At day 13, the viral load was only
log102.2 less than baseline. Nucleotide analogues have two advan-
tages over other classes of inhibitors. There is a high genetic barrier
to resistance selection, due to the HCV RNA polymerase being
highly speciﬁc for its natural substrates and template. This speci-
ﬁcity can be altered but only under extreme evolutionary pressure
(see Section 3). Also, nucleotide analogs often have pan-genotype
activity because the active site of the HCV NS5B polymerase is so
highly conserved.
As an example of how prodrugs can impact a discovery pro-
gram, allowing for more targeted delivery and for the optimization
of the intrinsic properties of the triphosphate, Adrian presented the
history of the GS-6620 program. The C-adenine analogue (20-C-Me-
4-aza-7,9-dideazaA, C-Nuc1) was compared to the corresponding
N-nucleoside, MK608. In a genotype1b replicon assay, the EC50 val-
ues were 2.5 lM and 0.08 lM respectively. However, their triphos-
phates were equally effective against HCV NS5B polymerase (IC50
values both 0.3 lM). In the replicon system, the triphosphate of
the N-Nuc (MK608) was formed more efﬁciently than that of the
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in primary human hepatocytes, C-Nuc1 was phosphorylated to the
triphosphate more efﬁciently than the N-Nuc (MK608). This illus-
trates the importance of using primary human cells.
C-Nuc1 seemed to have a benign in vitro toxicity proﬁle, includ-
ing not inhibiting the mitochondrial DNA polymerase-gamma, but
it had very signiﬁcant toxicity in animals. In a collaboration
between Gilead and Craig Cameron at Pennsylvania State Univer-
sity, the researchers sought to identify the toxicity target(s) for
ribonucleotide analogues, including C-Nuc1 and others that had
been stopped in Phase II trials. These studies showed a correlation
between C-Nuc1 and the Phase II candidates, R1626, NM283 and
BMS986094/IDX184. All the latter were efﬁciently incorporated
into RNA by the mitochondrial RNA polymerase (>70% of the corre-
sponding natural nucleotide). The triphosphate of C-Nuc1 was also
an efﬁcient substrate (22% the rate of ATP). In contrast, the active
nucleotide analogs, formed by drugs approved for the treatment
of HCV, were poor substrates. Ribavirin was poorly incorporated
(about 5%) and sofosbuvir was below the limit of detection
(= 0.02%). More extensive in vitro and cell culture evaluation of
the compounds could have saved the expense of taking them into
clinical trials.
Understanding that the mitochondrial RNA polymerase is an
important target for ribonucleotide toxicity, the Gilead team
sought analogs that were not incorporated by this polymerase.
Adding a CN group to the 10 position of C-Nuc1 did not change
its activity as an HCV NS5B polymerase inhibitor (IC50 0.3 lM)
but it did reduce incorporation in the mitochondrial RNA assay
(<0.02%). However, in the absence of a nucleotide prodrug to
bypass the ﬁrst phosphorylation step, the resulting di-substituted
nucleoside analog would not be a drug candidate because it was
not efﬁciently activated in cells. Application of a nucleotide pro-
drug strategy allowed this nucleotide to be pursued further. Oral
absorption, delivery of the monophosphate into hepatocytes and
high hepatic extraction were criteria used as part of the prodrug
optimization process. A nucleotide prodrug, GS-464335 (a mixture
of diastereoisomers at phosphorous) was well absorbed in dogs
(>80%). Comparing the pre-hepatic and post-hepatic plasma drug
levels, about 80% of the absorbed drug was taken up by the liver.
Inside cells, GS-464335 was converted to the corresponding mono-
phosphate which was efﬁciently converted to the triphosphate. At
24 h, the triphosphate levels remained about 2-fold above the IC90
value. A pure stereoisomer was selected and later named GS-6620.
In a Phase II trial (900 mg, bid 5 days), the mean reduction in HCV
load was about log101.5. Two subjects achieved HCV RNA <25 IU/
ml. However, the pharmacokinetics and antiviral responses were
highly variable. Whereas the activity results were disappointing,
clinical proof of concept was observed in terms of safety. GS-
6620 did have a markedly improved safety proﬁle relative to C-
Nuc1, progressing through chronic toxicology studies in rats and
dogs at relatively high doses.
The story of GS-6620 illustrates both how nucleotide prodrugs
enable further progression of candidates and also the complexity
of predicting the behavior of nucleotide prodrugs across species.
One wonders what cell culture test or animal model may have pre-
dicted such variability. When selecting famciclovir as the prodrug
for penciclovir, one potential prodrug was rejected because the
pharmacokinetics in rats varied widely between individual animals
(Vere Hodge et al., 1989). A recent publication by Adrian and his
team highlights the metabolism of GS-6620 by carboxylesterase
2, an enzyme highly expressed in the human small intestine but
not uniformly expressed in different animal species, as a possible
reason for the highly variable and suboptimal intestinal absorption
of GS-6620 in humans (Murakami et al., 2014).The focus of Adrian’s talk then switched to HIV. Over the last
15 or 20 years in North America, the HIV-infected population has
been changing, becoming older (now 33% over 50 years old vs
<10% in 1995) and more likely to be obese (in every USA
state, >20% adults with BMIP30). This has led to a shift in the
focus of antiretroviral therapy (ART), from solely control of HIV
replication to now include tolerability in older, possibly obese,
patients.
The ﬁrst example given for HIV was how application of a differ-
ent prodrug strategy can markedly change the distribution even
when delivering the same pharmacologically active nucleotide
analog. The ﬁrst approved prodrug of tenofovir (TFV) was TFV diso-
proxil fumarate (TDF). More recently, TFV alafenamide (TAF) has
been progressed into clinical development. A key difference in
the properties of the two prodrugs is their stability in plasma, with
half-lives of 0.4 and 90 min, respectively. Even with a short half-
life, TDF gave better delivery of TFV into cells, as indicated by the
HIV EC50 values in cell culture assays but there clearly was room
for improvement; the EC50 values for TFV, TDF and TAF are 1.2,
0.015 and 0.003 lM respectively. Whereas the gain in cell culture
EC50 value may be modest, this is not the only gain. The increased
stability of TAF allows it to load on-target cells and tissues (e.g.,
lymph nodes) for a longer period of time resulting in increased
lymphoid cell and tissue levels at greatly reduced circulating TFV
levels, leading to less exposure to off-target tissues (e.g., kidney).
In monotherapy studies after oral dosing with TDF (300 mg) and
TAF (25 mg), the plasma TFV AUC is reduced from 1920 to
268 ng.h/ml respectively whereas the reduction in HIV load from
baseline is improved, from log100.97 to log101.46 copies/ml,
respectively, reﬂecting the more efﬁcient delivery of TAF to target
cells and tissues. Clearly the lower dose of TAF (25 mg) relative to
TDF (300 mg) will give TAF a marked advantage when considering
combination pill therapy.
Understanding how marked a difference a prodrug can make
from the TAF example, Adrian went on to describe how a prodrug
approach transformed a new nucleotide project in which intrinsic
properties of the pharmacologically-active nucleotide analog were
optimized. Their starting point was GS-2128 (D4APi), which had
good activity against both wild-type and resistant HIV strains but
was an active inhibitor of mitochondrial polymerase-gamma. On
comparing the known structures of HIV RT and mitochondrial
polymerase-gamma, differences in the 20-binding pocket were
noted. This led to GS-9148 in which 20-F was added to GS-2128
(Fig. 8).
Compared to TFV, GS-9148 was about 3-fold less active against
wild-type HIV but maintained better activity against resistant
strains (K65R and multiple thymidine analog resistance muta-
tions). Most importantly, it was inactive (IC50>300 lM) against
mitochondrial polymerase gamma. More than 50 prodrugs were
synthesized and evaluated in metabolism studies and in dogs
(intravenous and oral administration). Then the enantiomers were
tested separately in dogs. This led to the selection of GS-9131.
Whereas TFV is efﬁciently utilised by renal uptake transporters,
GS-9148 was poorly taken into the kidney. No adverse renal ﬁnd-
ings were observed with the prodrug (GS-9131) in 28-day studies
in rats, dogs and monkeys at the highest doses tested (300 mg,
20 mg and 30 mg/kg daily, respectively).
In summary, this work has given examples of the prodrug
approach being used successfully both to increase selectivity (by
loading on-target tissues vs off-target tissues) and to increase
activity (via by-passing metabolic constraints). Adrian presented
cases in which a prodrug strategy was able to fulﬁl the full poten-
tial of a selective, active triphosphate analog and enable its further






























Fig. 8. Structures of GS-2128, GS-9148 and GS-9131.
Fig. 9. Keynote speakers David Margolis (left) and Myron Cohen (3rd from left)
with Phil Furman (ISAR President, 2nd from left) and Bob Buckheit (ISAR President-
Elect, right).
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The keynote speakers were David Margolis and Myron Cohen
(Fig. 9).5.1. Eradication therapies for HIV: building the critical path
David Margolis, University of North Carolina, NC, USA
In HIV-infected patients, there is a long-lasting reservoir of HIV
in the form of integrated viral DNA in resting CD4+ memory cells of
the host immune system. Therefore, even if it were possible to
eliminate 100% of viral replication, a reservoir of HIV would
remain. There may be reservoirs in other long-lived cells. To date,
there is only one known HIV patient who has been cured of his
infection, the ‘‘Berlin Patient’’. He was treated for cancer by chemo-
therapy followed by a bone-marrow transplant. Being CCR5 +/,
the chemotherapy had a greater chance to remove all the CCR5+ve
cells. The bone marrow donor was CCR5ve. Although this patient
continues to have no sign of HIV infection, this is hardly a viable
treatment option for most HIV-infected patients.
Even in subjects with HIV replication well controlled by ther-
apy, 70% have detectable plasma viremia which does not appear
to decay over time (at least two years). To improve the sensitivity
of the assay for HIV, 4 billion lymphocytes are mixed with antibodyattached to magnetic beads. This selects for the CD4+ T cells, about
0.2–1 billion cells. The limit of detection is 1 copy of HIV RNA/mil-
lion cells, limit of quantitation is 10 copies/million cells.
To reduce the reservoir of HIV, it was suggested that activation
of integrated HIV in resting CD4+ T cells would give renewed HIV
RNA synthesis and possibly result in cell death either due to viral
cytopathic effects or resulting from HIV-speciﬁc immune
responses. A small clinical trial was set up to test this hypothesis.
Vorinostat (VOR), a clinically approved drug for treating certain
cancers, has been shown to bind to the active site of histone
deacetylases. After a single dose, there was an increase in HIV
RNA (1.5 to 5-fold, mean 2.6-fold). Of these subjects, 5 elected to
continue with multiple doses. From the 11th to 22nd VOR dose,
acetylation of histones and activation of HIV RNA synthesis became
refractory to therapy. Also, it is not known what proportion of cells,
with latent HIV, can be activated. Whereas a single VOR dose did
increase the expression of HIV RNA, this is not an effective therapy
for removing the HIV reservoir.
5.2. HIV prevention 2014–2021: managing aspiration and expectation
Myron Cohen, University of North Carolina, NC, USA
Myron noted that there are 2.5 million new HIV infections each
year. In this context, anal sex may be an important factor because
just one or a few virions of HIV can be infective; within 3 weeks,
there is rapid virus replication throughout the body and latent
HIV reservoirs of ‘‘founder virus’’ are already formed. Although anal
sex has been associated with homosexual couples, Myron pointed
out that it is not uncommon amongst heterosexual couples.
Although behavioral education should be encouraged, it can
never be the whole answer. Various approaches to the prevention
of HIV transmission are being evaluated. Monoclonal antibodies,
broad neutralising antibody (bNAB) and vaccines may have poten-
tial for prevention of transmission, but most progress is being
made with dapivirine rings containing TDF. These are designed to
stay in the vagina for a month. Phase III trials are ongoing. A
long-acting HIV integrase inhibitor, GSK 1265744 (generally
known as GSK 744), is administered i.m. once every 3 months; a
two-year safety trial will be required. Phase I trial has been com-
pleted and Phase II trial is being planned.
By analogy with tuberculosis therapy, in which the infectious
state is disabled prior to a complete cure, one wonders if HIV trans-
mission rates may decrease with effective ART use. In 2005, the
HIV Prevention Trials Network (HPTN) initiated a study (HPTN
052) which enrolled 1,763 HIV sero-discordant couples (couples
that have one member who is HIV-infected and the other who is
HIV-uninfected), mostly (97%) heterosexual couples. The infected
partner had to be well enough not to require immediate ART.
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ART. Both groups received the same care including counselling on
safe sex practices, free condoms, treatment for sexually transmit-
ted infections and regular HIV testing.
In May 2011, it had been announced that there had been 27 HIV
transmissions in the delayed ART group (877 couples) compared to
only 1 in the immediate ART group (886 couples), a 96% reduction.
In these 28 cases, the HIV strain was linked to the partner. This is
the ﬁrst randomised clinical trial to show that treating an HIV-
infected individual with ART can reduce the risk of HIV transmis-
sion to an uninfected partner. Even with ‘‘safer-sex’’ counselling,
there were 60 pregnancies in the delayed ART group, despite that
group havingmore incentive for safer-sex. Following the announce-
ment of this result, all infected participants were offered ART.
Myron reported the 10th annual review of this study. In the
delayed ART group, there had been a total of 28 cases of HIV trans-
mission with the HIV strain linked to the partner and 11 cases of
unlinked transmission. In the one case of HIV transmission in the
immediate ART group, infection had been detected at day 85 of the
study and further investigation suggested that the infection event
was on day 1. Clearly, early ART is highly beneﬁcial. CDC guidelines
now recommend that all HIV infected patients should have ART.6. Mini-symposium: hepatitis B virus
6.1. Hepatitis B treatment: challenges and opportunities
Anna Lok, University of Michigan, MI, USA
The number of people infected with HBV world-wide, as esti-
mated by the WHO and CDC in 2007, was between 223 and 240
million, but was declining due to vaccination. In the USA, vaccine
use has led to a steady decline in the rate of new infections,
decreasing from about 10/100,000 residents in the 1980s to about
1/100,00 today. In contrast, the prevalence of chronic hepatitis B
among immigrants remains high, with no decreasing trend.
When infection is acquired early in life, chronic infection is the
norm. High viral load is associated with progression to liver cancer.
There are 7 FDA-approved drugs to treat chronic HBV infection,
including entecavir (ETV), emtricitabine (FTC) and TDF. With several
years of continuous therapy, HBeAg loss is achieved in about 40% of
patients but HBsAg loss (the ultimate goal, seen as a ‘‘cure’’) is still
a distant prospect for most patients. However, cirrhosis can be
reduced by long-term antiviral treatment. In one TDF trial at 5 years,
344/348 patients had a liver biopsy which showed that 73% of
patients had improvedﬁbrosis scores (P2 units) and thatmost other
patients had noworsening. TDF has now been used for 6 years with-
outdetectingHBV resistance,making it oneof theﬁrst linedrugs. TDF
is generallywell tolerated but its rare side effects include nephrotox-
icity (see above for a possible switch to TAF when it is approved),
reduction in bone mineral density and very rarely lactic acidosis.
Despite the major progress made in HBV therapy, there remain
various challenges. One is cost, about $60,000–$72,000 for 5-year
TDF therapy. Pharmacy claims show that adherence is a problem;
doses used are less than doses prescribed. There is a lack of accu-
rate prediction of how HBV disease will progress in individuals.
HBV DNA can be integrated into the human genome at an early
stage of infection. Fortunately, the integrated viral DNA is usually
not the complete viral genome and patients, who achieve HBsAg
loss, rarely relapse.6.2. The hepatitis B virus life cycle: recent achievements and challenges
Stefan Mehrle, University of Heidelberg, Germany (Stephan
Urban, Head of Hepatitis B Research Group, University of Heidel-
berg, was originally scheduled to give this presentation).Some chronic HBV-infected subjects are co-infected with hepa-
titis delta virus (HDV). This is a defective virus that replicates only
in the presence of HBV. Current antiviral drugs do not inhibit HDV.
Recently, heparan sulphate proteoglycan (HSPG) has been shown
to be essential for binding both HBV and HDV to primary
hepatocytes.
In 2012, human sodium taurocholate co-transporting polypep-
tide (hNTCP) was identiﬁed as a functional receptor for HBV and
HDV. hNTCP is also designated as a solute carrier protein 10A1
(SLC10A1). hNTCP was shown to be a binding factor for the preS1
domain of the HBV L envelope protein. This interaction was found
to be essential for HBV and HDV infection. Whereas HBV replica-
tion is poor in cell lines derived from hepatocytes (e.g. HepG2
and Huh-7) in which hNTCP is usually weakly expressed, HBV rep-
lication is possible in primary human hepatocytes. The critical dis-
covery was that over-expression of hNTCP in HepG2 or Huh-7 cells
conferred susceptibility to HBV and HDV infection.
Myrcludex-B is a lipopeptide derived from amino acid residues
2–48 of the preS1 region of the HBV L protein. Because it quickly
(within 5 min) targets the liver, it is being developed for liver imag-
ing and for drug targeting. It also acts as an entry inhibitor for HBV
and HDV by interrupting binding between the HBV L protein and
hNTCP. It speciﬁcally inhibits hNTCP-mediated taurocholate trans-
port but the effect on HBV replication is much greater. Myrcludex-
B activity has been investigated in vivo using SCID mice reconsti-
tuted with human hepatocytes. With prophylactic treatment, not
one infected hepatocyte was seen. Following therapeutic treat-
ment, at week 6 post-infection, there were a few isolated infected
cells. After the end of therapy, the infection seems to spread but
only to neighboring cells.
Myrcludex-B has been synthesised on a 100 g scale. Toxicology
evaluation in 3 chimpanzees has been completed and clinical trials
have been initiated. In a Phase I trial using a 20 mg dose, myrclu-
dex-B was well tolerated. Results of a further Phase I trial are
due to be reported later this year (2014). A dose-ranging Phase II
trial has been started.6.3. Immune regulation and co-stimulation in HBV-infected patients:
an uneasy truce
Kyong-Mi Chang, University of Pennsylvania, PA, USA
Anti-HBs antibodies clearly play a critical role in controlling
HBV disease. Their presence has been accepted as an indication
of an ‘‘effective cure’’. However, these antibodies appear late in
the disease course and so they must have a limited role in the early
stages of the disease. What is the role of T-cell responses? In con-
trast to other viruses, there is a delayed onset, about 4–8 weeks
rather than days. CD4+ T cells regulate the adaptive response,
CD8+ T cells attack HBV-infected cells.
The National Institute of Diabetes and Digestive and Kidney Dis-
eases (NIDDK), part of the USA National Institutes of Health (NIH),
is supporting a prospective clinical trial to investigate HBV-speciﬁc
T cell responses during the course of HBV disease. There are no
clear T cell differences relative to HBV genotype. The T cell
responses are highest during acute HBV infection. During the
chronic phase of HBV disease, T cell responses remain suppressed.
In conclusion, there are a lot of players in the immune control of
HBV infection but their relative contributions and how they adapt
to control HBV replication are still largely unknown.6.4. Diversifying the hepatitis B pipeline: current efforts to explore
novel mechanisms
Andrea (Andy) Cuconati, Institute for Hepatitis & Virus
Research, Pennsylvania Commonwealth Institute, PA, USA
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highly effective in controlling the infection but a ‘‘cure’’, as deﬁned
by HBsAg seroconversion, has remained elusive. At best after
5 years, the rate is about 25%. Other approaches are needed. Myr-
cludex-B (see Section 6.2) is the lead entry inhibitor. NVR-1221,
an encapsidation inhibitor, is entering clinical trials. In addition.
studies with novel nucleotide analogues are ongoing.
The HBV ﬁeld has been transformed recently by the introduc-
tion of cell-based antiviral assays. Stefan Mehrle (see Section 6.2)
has been leading the way. The assay read-out will need to be opti-
mized for high-throughput screening (HTS) but, already, the assay
has shown some ‘‘hits’’. A few compounds inhibited encapsidation
of viral RNA. (The HBV virion contains partly double stranded (ds)
DNA but the reverse-transcription from RNA to DNA occurs within
the capsid.) Within the cell, HBV DNA is transported into the
nucleus where the viral DNA forms covalently closed circles
(cccDNA). Two speciﬁc inhibitors of cccDNA formation have been
found. Current nucleotide anti-HBV compounds do give large
reductions of HBV DNA in plasma but only a minimal reduction
in levels of the HBs antigen (about log100.1). In contrast, one
‘‘hit’’, HBF-0259 inhibited surface antigen production but not geno-
mic replication. Structure–activity-relationship (SAR) studies have
given the current lead compound, HBV-0215. In conclusion, the
cell-based assay, with complete replication of HBV, has markedly
improved the screening for anti-HBV compounds although further
optimization is still needed to give HTS capability.
6.5. HBV capsid protein: biology and potential as a drug target for anti-
virals
Adam Zlotnick, University of Indiana, IN, USA.
Over the last few years, there has been much progress towards
understanding the critical role of the HBV core protein – it is much
more than just a protective coat for the genome because it plays a
major role in the HBV life cycle. The core protein, being 183 amino
acids long, is known as Cp183. The ﬁrst 149 amino acids are
involved in core assembly whereas the last 34 residues, rich in ser-
ines and arginines, bind to RNA. Phosphorylation of the serines,
particularly S155, S162 and S172, is required for speciﬁc packaging
of full length HBV RNA complexed to the polymerase (reverse
transcriptase – pregenomic RNA; RT-pgRNA).
This RT-pgRNA complex initiates encapsidation. The core con-
sists mainly of Cp183 but also includes other proteins (about
0.5%). Adam showed us a computer model of the core, using differ-
ent colours to highlight the various critical components. Inside the
core, the area of highest density (highlighted in red) represented
the polymerase which was attached to the inner surface of the
core. The ‘‘other proteins’’ in the core were shown in blue. The cur-
rent thinking is that the polymerase, initially acting as a reverse
transcriptase, is attached to, and guided by, an ‘‘inside railway
track’’. This enables the polymerase to jump to the other end of
the RNA to start the reverse transcription into DNA and then jump
again to the other end to start, but never complete, the replication
of the complementary DNA strand. The self-assembly of the core is
an energetically ‘‘downhill’’ process. Somewhat surprisingly, it is
possible to get mutations in which the core is even more stable
but the RT activity is reduced.
The phenylpropenamide derivative, AT-130, ﬁlls a pocket in the
core and so stabilizes it, similar to the change in amino acids in the
mutants. In the presence of AT-130, core assembly occurs faster;
hence it is known as a core assembly enhancer (as Adam men-
tioned, not a term much loved by industry, their preference is for
core assembly inhibitors). Regardless, the whole capsid structure
changes. The binding of only a few drug molecules is required to
make the core non-functional. It seems that it is easier to ﬁnd com-
pounds to enhance core assembly than inhibitors.6.6. Targeting cccDNA to cure chronic hepatitis B
Massimo Levrero, Sapeinza Universita’ di Roma, Italy.
The current HBV therapies of choice are TDF alone or with ETV.
These drugs have an extensive safety record with use up to 7 years.
However, as for other nucleoside/nucleotide analogs, there is only
a limited (about 1 log10) reduction in the levels of HBV cccDNA. The
half-life of HBV cccDNA seems to be long, but is still unknown.
HBV replication parallels host gene expression, in that they
involve the acetylation of histones, for example H3 and H4. Both
host transcription factors and viral proteins bind to the cccDNA.
Massimo summarized various assays to study different stages of
cccDNA during the replication cycle. Potentially, these assays
would allow the study of various approaches: to reduce or clear
cccDNA, to silence cccDNA or to prevent the formation of new
cccDNA so that it would eventually be removed by dilution and cell
death.
For proof-of-concept, known ‘‘epigenetic’’ compounds, which
act as transcription inhibitors, have shown that cccDNA can be
silenced. By reducing histone acetylation, the cccDNA becomes
too compact to allow transcription. This approach mimics, partly,
therapy with interferon. This research is still at an early stage.
6.7. Animal models of hepatitis B disease
Due to time constraints, the next two speakers were asked to
present brief summaries.
John Morrey (Utah State University, UT, USA) described four
mouse models but all stages of the life cycle of HBV can be studied
only in the chimeric mouse model, in which human hepatocytes
are used. However, this model lacks the potential to study the
immune system and it is very expensive.
Stephan Menne (Georgetown University, DC, USA) described
the woodchuck model. Woodchuck hepatitis virus (WHV) resem-
bles the human virus and the disease in animals has many similar-
ities to that in humans. Neonatal infection becomes chronic in
about 60–75% of cases. These chronic cases have virtually a 100%
life-time risk of developing cancer, the time scale being about
1 year of chronic infection, followed by cancer at years 3 to 4.7. Mini-symposium: Research Triangle Park
7.1. Biophysical mechanisms and methods of evaluation in HIV
prevention science
The use of microbicides is an active area of research for the pre-
vention of transmission of HIV. David Katz (Duke University, NC,
USA) described how mathematical models may aid drug product
design. For example, if it is assumed that the microbicide gel is
400 microns thick, the epithelium is 200 microns and the stroma
(connective tissue) is 3000 microns and if the partition coefﬁcient
between gel and epithelium in known, then it is possible to model
drug transfer and suggest how various other parameters, for exam-
ple the size of the subject, may modify drug delivery.
It is important that different disciplines work together, for
example biophysicists with behavioral scientists. Biophysics can
help an understanding of complex physical phenomena but human
behavior can be both complex and highly variable.
7.2. Novel animal model platforms of human disease
Ralph Baric (University of North Carolina, NC, USA) noted that a
particular infective agent, for example norovirus (NoV), may cause
subclinical or serious disease in different individuals. In general,
animal models are designed to give consistent outcomes rather
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jects. In a collaborative effort, mice from 8 ‘‘founder’’ strains,
including 3 wild-derived strains, were selected. The 5 founder lab-
oratory strains were all derived ultimately from a single female
mouse ca 1900. The susceptibility of the 8 founder strains to severe
acute respiratory syndrome coronavirus (SARS-CoV) differed
widely (LD50P106–102). The founder strains were cross-bred.
Although ca 90% of the genes was equally distributed among the
new mouse lines, there were gene combinations not seen previ-
ously. After infecting mice from the different founder strains with
a constant SARS-CoV inoculum and measuring virus load at a set
time after infection, there was a correlation between virus load
and disease (as measured by vascular cufﬁng). It was possible to
relate the effect to chromosomes 3 (27%) and 13 (20%). Hopefully,
identiﬁcation of the important genes may be achieved. By keeping
the virus inoculum constant, this system better represents the clin-
ical spectrum of disease.
When using this system to evaluate a potential vaccine, it was
found that mice, under the age of one year, could be protected.
However, there was a range of effectiveness, from good protection
to inactive. These variations may give a representation of human
diversity.
7.3. Did we put the cart before the horse? Clinical pharmacology
insights into HIV prevention trial outcomes
Angela Kashuba, University of North Carolina at Chapel Hill, NC,
USA
In four clinical studies, Truvada [a combination pill containing
TDF and emtricitabine (FTC)] was taken once daily to prevent
HIV transmission, known as pre-exposure prophylaxis (PrEP). The
adherence rates were unexpectedly poor in all four studies, partic-
ularly low in the study including at risk women. For example in
one study, ‘‘high adherence’’ was deﬁned as subjects taking at least
80% of drug doses and was achieved by only 54% of subjects. Pos-
sible reasons may have been the apparent risk of side-effects (the
long consent form included 7 pages of side-effects) and the percep-
tion that the subjects, as individuals, were not particularly at risk of
infection by HIV. Importantly, the trial did conﬁrm the concept that
PrEP could be effective. There was >90% protection in those sub-
jects generally taking 7 doses/week and there was some protec-
tion, albeit much less, in subjects taking 2 doses/week.
Adherence rates, reported by subjects, were appreciably higher
than the rates evidenced by drug blood level measurements taken
just before the next dose (i.e. 24 h after previous dose). In an
attempt to better understand and model these data, the drug con-
centrations (TDF/TFV and FTC) in various tissues were measured.
The ratio between drug concentrations in blood and tissue samples
differed greatly for TDF/TFV, with less variations for FTC. Concen-
tration ratios of TDF/TFV were about 50 in rectal tissue but only










Fig. 10. Structure of BCX4430.When considering the possible consequences of missed doses,
the time scale for HIV infection is an important factor. It is thought
that HIV takes about 1–3 h to reach the epithelial cells. Clearly,
adherence is a critical factor for efﬁcacy and so a real-time objec-
tive method for measuring adherence is urgently needed before
further clinical studies are initiated.7.4. The novel nucleoside analog BCX4430 exhibits broad-spectrum
antiviral activity and confers post-exposure protection against Ebola
and Marburg viruses
Travis K. Warren, USAMRIID, Fort Detrick, MD, USA
Ebola and Marburg viruses are members of the ﬁlovirus family.
Even in recent outbreaks of these diseases, including the current
Ebola epidemic in West Africa, care workers are becoming infected
and dying. Drugs, which are being investigated for treating these
diseases, are progressed under the FDA ‘‘Animal Rule’’.
BCX4430 is a C-nucleoside adenine analog (Fig. 10) which is
being progressed by BioCryst Pharmaceuticals Inc. (Warren et al.,
2014). In cell culture assays, BCX4430 is active against Ebola and
Marburg viruses, (EC50 ca 1 lM). With BCX4430 at 30 lM, there
was no detectable incorporation into host DNA or RNA. In rats,
BCX4430 is efﬁciently activated (phosphorylated) to the triphos-
phate. In a primer-extension assay, there is some read-through
beyond a single residue of BCX4430, but there is effective chain
termination after the ﬁrst BCX4430 residue where the template
has two consecutive uridine residues.
BCX4430 has been tested in rodent and nonhuman primate
models of Marburg hemorrhagic fever. In mice, there was a dose
response (30, 20, 3.3 and 1.1 mg/dose, bid) with full protection at
the two higher doses (survivors, 100%, 100%, 95% and 83% respec-
tively). In an experiment with dosing starting at different times
(4 h pre-infection, 24, 48, 72, 96 and 120 h post-infection vs pla-
cebo), the placebo-treated mice died on days 6, 7 and 8 with one
survivor (10%). In the treated groups, the percent survival was
80, 100, 80, 100, 100 and 30, respectively. In guinea pigs,
BCX4430 (bid) with treatment starting at different times (1 h
pre-infection, 24, 48 and 72 h post-infection) there was full protec-
tion (100% survival) for the pre-infection and 24 h groups, with
reduced efﬁcacy at the later start times.
In cynomolgus monkeys, BCX4300 treatment was started at 1,
24 and 48 h post-infection. In the placebo group, all 6 animals died
within days 9 to 12. In all the treated groups, virus loads were
reduced by more than log103. There was one late death in the 1 h
group but the other 17 monkeys survived. Various markers of
potential organ damage were reduced in all treated groups.
Encouraged by these results, 14-day toxicology trials have
recently been completed without any serious concerns. BioCryst
is developing BCX4430 under the FDA Animal Rule and IND-
enabling work is ongoing.
When asked about viral resistance, Travis explained that it is
not ethically permissible to create resistant strains of Marburg
virus, but samples collected from the monkeys are being
sequenced to look for mutations indicative of drug resistance. As
yet, mitochondrial toxicity has not been examined.8. Challenges in HIV infection, treatment and prevention
8.1. Can we cure HIV infection?
Mario Stevenson, University of Miami, Miami, FL, USA
Even after successful and prolonged ART, invariably plasma HIV
load increases within 20 days of stopping therapy. Of all the mil-
lions of HIV-infected people, there has been only one documented
cure – the ‘‘Berlin’’ patient (see above). Two Boston patients, who
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been ‘‘cured’’ but HIV was detected after 70 and 200 days,
respectively.
Latent HIV can survive in various long-lived cells for decades,
especially in memory T cells. When these cells proliferate, the inte-
grated HIV genome is duplicated as the cell divides and the cells
survive so long as HIV remains silent. Compounds known to acti-
vate all T-cells are too toxic to become a clinical therapy. However,
latency-reversing agents (LRA) have greater speciﬁcity, ideally acti-
vating only the integrated HIV, leading to the death of HIV-contain-
ing T-cells. There remains another possibility (perhaps a less
popular view) that there is continued low rate of HIV replication.
Two clinical studies have been initiated in subjects with undetect-
able plasma HIV levels. Raltegravir, an HIV integrase inhibitor, was
added to the background therapy. Latent HIV is mostly integrated
into host DNA but HIV may also form episomal circular DNA. The
proportion of the circular form increases with raltegravir treat-
ment. In the two clinical studies, 13/45 and 9/15 subjects, respec-
tively, had detectable HIV circles which then decayed. This implies
that some de novo infection of cells is ongoing. On the other hand,
ART works well, with no evidence of sequence evolution in the HIV
circles at 48 weeks. Is it possible that raltegravir is inducing a sin-
gle round of HIV replication, to give an increase in HIV circles?
8.2. Potential therapeutic approaches for the cure of HIV infection
Derek Sloan, Gilead Sciences, Foster City, CA, USA
Like vorinostat, (VOR), romidepsin (RMD) is a histone deacetyl-
ase inhibitor which is used clinically to treat cancer. Memory CD4+
T cells were taken from HIV subjects on suppressive ART; ex-vivo
treatment with RMD (40 nM) induced a 6-fold increase in intracel-
lular HIV RNA which persisted for 48 h. In contrast, a much higher
concentration of VOR (1 lM) gave a 2 to 3-fold lower response
which was only transient. RMD also increased levels of extracellu-
lar HIV RNA and virions. Encouragingly, this ex-vivo induction of
latent virus was seen at RMD concentrations that are below the
levels of drug achieved in humans by clinical doses of RMD.
Accordingly, in a Phase I/II trial in HIV-infected subjects on ART,
RMD gave a better and more sustained response than VOR. About
1.5% of cells containing HIV provirus were activated. Although this
is far too low a percentage to eliminate the latent HIV reservoir, it
is hoped that combination of such LRA, which give improved
results in ex-vivo cell assays, may give better clinical efﬁcacy.
Gilead scientists have started screening for novel LRAs. ‘‘GS-1’’
has been identiﬁed as a hit by HTS. Research on this lead is at a
very early stage. Gilead workers are also investigating other
approaches. For example, GS-9620 is a Toll-like receptor 7 (TLR7)
agonist and it acts as an immune stimulator. Although it is being
evaluated in Phase II studies for the treatment of chronic HBV
infections, the potential effect on HIV reservoirs is being investi-
gated. In SIV-infected monkeys, oral dosing of TLR7 agonist
induced the activation of immune effector cells such as CD8+ T
cells and NK cells. Based on these data, TLR7 agonists are being fur-
ther investigated for their effect on latent SIV reservoirs in mon-
keys which have good virological suppression. Another approach
is to use anti-envelope antibodies. Broadly neutralising antibodies
(bNAbs) are very effective in preventing SIV infection when the
viral load is low but less effective against a high-load virus chal-
lenge. In addition, a prophylactic CMV-vector-based SIV vaccine
was effective in preventing SIV infection in rhesus monkeys. This
and similar vaccines are being tested in vivo for their effects on
the latent SIV reservoirs.
In summary, LRAs are able to activate HIV provirus in memory
CD4+ T cells and thereby may enhance the recruitment of immune
effector cells to destroy provirus-containing cells. However, a
‘‘cure’’ for HIV infection is still a distant prospect. Furthermore,latent HIV reservoirs are heterogeneous and so a combination of
approaches will likely be required.
8.3. Animal models of HIV infection
Gerardo Garcia-Lerma, Centers for Disease Control and Preven-
tion, Atlanta, GA, USA
Proof-of-concept studies for PrEP, are mostly conducted in non-
human primates. These can be used either to model a single high-
dose infective challenge or repeated low inoculations, about 10–50
tissue culture infective doses (TCID50).
Since 2005, rhesus macaque models have been used in a long
series of investigations. In a study, in which the monkeys were
treated daily with either oral TDF or TDF/FTC and given a weekly
SIV inoculum rectally, TDF/FTC gave a longer delay in infection
than did TDF alone. When using the vaginal infection route, TDF/
FTC gave 100% protection. In contrast, there was far less protection
in clinical trials – why? One possible reason may have been that
women were having the contraceptive injection, depot medroxy-
progesterone acetate (DMPA). A study, in macaque monkeys given
DMPA, conﬁrmed that dosing with TDV/FTC gave good drug levels
in plasma and in vaginal secretions. Therefore, this did not explain
the poor protection in the clinical trial.
The macaque model has been used successfully to investigate
various situations that are presented in the clinic. When macaques
were co-infected with SIV and a bacteria and treated with TDF/FTC
for 12 weeks, there was good, but not complete, protection (80%).
With FTC-resistant virus, TDF/FTC remained protective. In this case,
FTC-resistant virus has increased susceptibility to TDF. With the
K65R mutant HIV, there was protection against a low inoculum
but only partial protection (ca 50%) against a high inoculum.
Whereas daily dosing seems to be acceptable for patients living
with HIV, another option for PrEP is desirable. GSK-1265744 (gen-
erally known as GSK-744) is an HIV integrase inhibitor. It can be
formulated with nano-particles to provide an injectable drug
depot. In the macaque model, GSK-744, injected once monthly,
gave full protection against repeated rectal and vaginal exposures.
Because metabolism of GSK-744 is much slower in humans than
macaques, it was expected to remain effective in humans for up
to three months. A Phase I study conﬁrmed that drug levels
remained above the predicted effective level with a 20-week dos-
ing interval. A Phase II trial is planned.
Another approach is to use vaginal rings, which have been in
clinical use as contraceptive devices for years. In the macaque
model, TDF-containing rings, replaced every 4 weeks, gave full pro-
tection. A Phase III trial has just been initiated. Another option,
elvitegravir (EVG) and TAF are being evaluated in a biodegradable
polymer. Although daily dosing with TDF/FTC has not proved suf-
ﬁciently successful as PrEP in clinical use, it has proved that PrEP
is an achievable aim and this has encouraged the progression of
other options.
8.4. Monitoring HIV drugs and viral reservoirs
Courtney Fletcher, University of Nebraska, Omaha, NE, USA
Atripla was the ﬁrst triple combination pill taken once daily for
HIV therapy. It contained TDF, FTC and efavirenz (EFV). The maca-
que model has been used to investigate the differing tissue distri-
butions of these drugs and how viral replication may be continuing
wherever the drug concentrations are lowest. There are two
approaches: tissue homogenates and tissue cells. Tissue homoge-
nates give both the intracellular and extracellular drug amounts.
From tissues, mononuclear cells (MNCs) are collected and the
intracellular drug concentration measured. This approach is pre-
ferred by Courtney but this option may be constrained by sample
size and the drug concentration may be underestimated. For exam-
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drug concentration is very low. Much higher raltegravir concentra-
tions are found when the MNCs are cleaned by a rapid spin through
oil. Comparing an oil spin and repeated washes, the oil process
gives higher drug levels, typically about 50% higher.
Following initial studies in macaques, a clinical study, in 32 sub-
jects, investigated distribution of the drugs from Atripla in periph-
eral blood mononuclear cells (PBMC) and various tissues (see
above). In 12/32 subjects, there are data on the time to reduce
HIV load to <48 copies/ml. In plasma, the time was 3–4 months.
In lymphoid tissues, there was a much slower rate of HIV decline.
Also, patient variability was noted, with the faster responders hav-
ing the higher drug levels.
A drug may be absorbed from the gastrointestinal tract either
going via the portal vein to the liver and then into blood circulation
or via the lymphoid system. Blood ﬂow is about 200 times faster
than lymphoid ﬂow. When the water/1-octanol partition-coefﬁ-
cient (logP) of a drug is <5, absorption tends to be via the blood
route. The prodrug approach can be used to alter absorption or,
as for TFV, stability of the prodrugs (TDF and TAF) can inﬂuence
the relative concentration in lymphoid tissues (see above).
9. Conclusion
This year, the three major award lectures exempliﬁed the
strength of ICAR, covering very different areas of research. John
Drach (Elion Award) described his journey through the early days
of antiviral research, which led to the identiﬁcation of novel modes
of antiviral action that had not been envisaged previously. Piet
Herdewijn (Holy´ Award) used evolutionary pressure to select
DNA polymerases that accept novel nucleoside analogs. The
replacement of thymine by 5-chlorouracil led to the generation
of a new form of E. coli. I suggest that this work has important
implications in conventional antiviral research. With HIV and
HCV protease inhibitors, the genetic barrier is limited by the ability
of the viral protease and its substrate (the viral polyprotein cleav-
age sites) to co-mutate so that the virus can become resistant to
the antiviral drug. So far, polymerase inhibitors have not suffered
the same fate but this work shows that a poor choice of nucleotide
analog could result in a resistant virus with a new type of RNA in
which the drug replaces a natural nucleoside. Adrian Ray (Prusoff
Award), describing work at Gilead, demonstrated how the prodrug
concept can markedly improve both the efﬁcacy and safety of
potential drugs. Their progress with HIV and HCV therapies has
been remarkable.
The keynote addresses tackled two emerging areas of HIV
research. David Margolis summarized work aiming to eradicate
HIV from infected subjects and Myron Cohen described current
progress with approaches to prevent HIV transmission. I found
both these presentations to be informative and stimulating. HIV
‘‘cure’’ still seems to be a distant prospect. In contrast, prior to
exposure prophylaxis (PrEP) has been shown to be an achievable
aim although the need for daily dosing is a barrier to success. Ger-
ardo Garcia-Lerma described recent progress which is likely to rad-
ically change the prospects for therapeutic convenience and
success. TDF-containing vaginal rings, which need replacing only
once a month, are being evaluated. Another exciting prospect is
GSK-744 which has been formulated as a long-lasting injection. A
Phase I trial conﬁrmed that the drug may be administered at 3-
month intervals. In the absence of a proven HIV vaccine, PrEP with
drugs has become the most promising strategy to reduce HIV infec-
tion rates among high-risk populations.
This conference also included three interesting mini-symposia:
‘‘Hepatitis B virus’’, ‘‘Research Triangle Park’’ and ‘‘Challenges in
HIV Infection, Treatment and Prevention’’. An innovation this yearwas a session devoted to the European Training Network, EUVIRNA
and introduced by Frank van Kuppeveld. All the 18 EUVIRNA fel-
lows, who attended ICAR, gave short presentations at this session.
For further information, please see the ISAR News (24.1) in the Sep-
tember issue of Antiviral Research for an account by Frank van
Kuppeveld.
For many years, the clinical symposium was, for me, a major
highlight of ICAR. In my report for the 2013 ICAR, I expressed a
hope regarding HCV therapy: ‘‘There is the prospect that the ﬁrst
nucleotide analogue will be licensed by the time of our next ICAR meet-
ing. The combination of a nucleotide analogue and a NS5A inhibitor
looks set to transform HCV therapy across all genotypes. As for HIV,
single-pill, once-daily regimens are following on quickly’’. On 6th
December 2013, Sofosbuvir (Sovaldi) was the ﬁrst nucleotide ana-
log to be approved in the USA by the Food and Drug Administration
(FDA) for treatment of patients with HCV. Approval by the Euro-
pean Union followed soon afterwards, in January 2014. A NS5A
inhibitor, ledipasvir, formulated as a single ﬁxed-dose combination
pill with sofosbuvir, is progressing quickly through clinical trials.
With such remarkable progress being achieved since the 2013
ICAR, I was disappointed to discover that there was no presenta-
tion on this topic at this year’s ICAR.
A paper (Soﬁa, 2014), which was part of a symposium in Antivi-
ral Research on ‘‘Hepatitis C: next steps toward global eradication’’,
emphasizes recent successes. After completing therapy, a sus-
tained virological response for 12 weeks (SVR12) is regarded as a
cure for HCV-infected patients. The combination of sofosbuvir/ledi-
pasvir has shown remarkable results in clinical trials, with SVR12
in the range 95–100% across genotypes. This combination was well
tolerated. A NDA for the sofosbuvir/ledipasvir combination pill was
submitted recently. I do not recall any previous antiviral trials in
which the ‘‘intention-to-treat’’ analyses showed 100% success
rates.
Perhaps similar to the HCV symposium in Antiviral Research, I
hope that the 2015 ICAR, which will be held in Rome, will have a
mini-symposium which will include an account of this remarkable
progress. It would be interesting to have an update on the clinical
impact of this combination therapy for HCV and to have an assess-
ment on the prospects for global eradication of HCV. Beside this
one disappointment, there were many excellent presentations
and I would like to add my thanks to the ISAR Ofﬁcers and Confer-
ence Committee for organizing another interesting and successful
ICAR.
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